

# Maria J Merino

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8185818/publications.pdf>

Version: 2024-02-01

189  
papers

10,368  
citations

38720

50  
h-index

38368

95  
g-index

190  
all docs

190  
docs citations

190  
times ranked

11176  
citing authors

#	ARTICLE	IF	CITATIONS
1	Using Prostate Imaging-Reporting and Data System (PI-RADS) Scores to Select an Optimal Prostate Biopsy Method: A Secondary Analysis of the Trio Study. <i>European Urology Oncology</i> , 2022, 5, 176-186.	2.6	24
2	Why Does Magnetic Resonance Imaging-Targeted Biopsy Miss Clinically Significant Cancer?. <i>Journal of Urology</i> , 2022, 207, 95-107.	0.2	29
3	A Cascaded Deep Learning-Based Artificial Intelligence Algorithm for Automated Lesion Detection and Classification on Biparametric Prostate Magnetic Resonance Imaging. <i>Academic Radiology</i> , 2022, 29, 1159-1168.	1.3	21
4	Reply by Authors. <i>Journal of Urology</i> , 2022, 207, 106-107.	0.2	0
5	Deep learning-based artificial intelligence for prostate cancer detection at biparametric MRI. <i>Abdominal Radiology</i> , 2022, 47, 1425-1434.	1.0	18
6	Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy. <i>Clinical Cancer Research</i> , 2022, 28, 1353-1362.	3.2	10
7	KLF3 and PAX6 are candidate driver genes in late-stage, MSI-hypermutated endometrioid endometrial carcinomas. <i>PLoS ONE</i> , 2022, 17, e0251286.	1.1	2
8	MPAPASS software enables stitched multiplex, multidimensional EV repertoire analysis and a standard framework for reporting bead-based assays. <i>Cell Reports Methods</i> , 2022, 2, 100136.	1.4	8
9	Differential VHL Mutation Patterns in Bilateral Clear Cell RCC Distinguishes Between Independent Primary Tumors and Contralateral Metastatic Disease. <i>Urology</i> , 2022, 165, 170-177.	0.5	2
10	A phase 2 study of bevacizumab, erlotinib, and atezolizumab in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) associated or sporadic papillary renal cell cancer (pRCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4604-TPS4604.	0.8	0
11	Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response. <i>Clinical Cancer Research</i> , 2021, 27, 429-437.	3.2	22
12	Changes in Magnetic Resonance Imaging Using the Prostate Cancer Radiologic Estimation of Change in Sequential Evaluation Criteria to Detect Prostate Cancer Progression for Men on Active Surveillance. <i>European Urology Oncology</i> , 2021, 4, 227-234.	2.6	14
13	MicroRNA Profiling of Morphologically Heterogeneous Clear Cell Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2021, 12, 5375-5384.	1.2	2
14	Bilateral disease and risk of prostate cancer progression in an active surveillance cohort.. <i>Journal of Clinical Oncology</i> , 2021, 39, 207-207.	0.8	0
15	Considerations for active surveillance in select Gleason grade group 2 patients: A preliminary study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 206-206.	0.8	0
16	MRI-guided fusion biopsy of the prostate resection bed among post-radical prostatectomy patients with rising PSA.. <i>Journal of Clinical Oncology</i> , 2021, 39, 208-208.	0.8	0
17	â€œCase of the Monthâ€™ from the National Cancer Institute, Bethesda, MD, USA: investigating genetic aberrations in a patient with high-risk prostate cancer. <i>BJU International</i> , 2021, 127, 171-174.	1.3	0
18	<sup>18</sup> Fluorodeoxyglucose-positron emission tomography/computed tomography for differentiation of renal tumors in hereditary kidney cancer syndromes. <i>Abdominal Radiology</i> , 2021, 46, 3301-3308.	1.0	4

#	ARTICLE	IF	CITATIONS
19	Pilot study of gadoxetate disodium-enhanced mri for localized and metastatic prostate cancers. <i>Scientific Reports</i> , 2021, 11, 5662.	1.6	2
20	Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 434-446.	1.5	10
21	Succinate Mediates Tumorigenic Effects via Succinate Receptor 1: Potential for New Targeted Treatment Strategies in Succinate Dehydrogenase Deficient Paragangliomas. <i>Frontiers in Endocrinology</i> , 2021, 12, 589451.	1.5	25
22	Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. <i>European Urology</i> , 2021, 80, 746-757.	0.9	50
23	Magnetic Resonance Imaging-Targeted and Systematic Biopsy for Detection of Grade Progression in Patients on Active Surveillance for Prostate Cancer. <i>Journal of Urology</i> , 2021, 205, 1352-1360.	0.2	3
24	Reply by Authors. <i>Journal of Urology</i> , 2021, 205, 1359-1360.	0.2	0
25	MRI-guided focal laser ablation of prostate cancer: a prospective single-arm, single-center trial with 3 years of follow-up. <i>Diagnostic and Interventional Radiology</i> , 2021, 27, 394-400.	0.7	9
26	Prognostic Features of Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy Based on Multiparametric MRI and Immunohistochemistry Analysis of MRI-guided Biopsy Specimens. <i>Radiology</i> , 2021, 299, 613-623.	3.6	11
27	The Risk of Prostate Cancer Progression in Active Surveillance Patients with Bilateral Disease Detected by Combined Magnetic Resonance Imaging-Fusion and Systematic Biopsy. <i>Journal of Urology</i> , 2021, 206, 1157-1165.	0.2	10
28	A deep-learning based artificial intelligence (AI) approach for differentiation of clear cell renal cell carcinoma from oncocytoma on multi-phasic MRI. <i>Clinical Imaging</i> , 2021, 77, 291-298.	0.8	25
29	Macronodular adrenal hyperplasia masquerading as an upper pole renal mass. <i>Urology Case Reports</i> , 2021, 37, 101603.	0.1	0
30	Risk of adverse pathology at prostatectomy in the era of MRI and targeted biopsies; rethinking active surveillance for intermediate risk prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 729.e1-729.e6.	0.8	6
31	Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancer. <i>Science Signaling</i> , 2021, 14, .	1.6	64
32	A Pilot Study of Dynamic <sup>18</sup> F-DCFPyL PET/CT Imaging of Prostate Adenocarcinoma in High-Risk Primary Prostate Cancer Patients. <i>Molecular Imaging and Biology</i> , 2021, , 1.	1.3	9
33	MRI-guided Biopsy in Active Surveillance of Prostate Cancer. <i>Journal of Urology</i> , 2021, , 101097JU00000000000002343.	0.2	2
34	Apical periurethral transition zone lesions: MRI and histology findings. <i>Abdominal Radiology</i> , 2020, 45, 3258-3264.	1.0	0
35	<sup>18</sup> F-DCFPyL PET/CT Imaging in Patients with Biochemically Recurrent Prostate Cancer After Primary Local Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 881-889.	2.8	38
36	Prospective Evaluation of <sup>18</sup> F-DCFPyL PET/CT in Detection of High-Risk Localized Prostate Cancer: Comparison With mpMRI. <i>American Journal of Roentgenology</i> , 2020, 215, 652-659.	1.0	22

#	ARTICLE	IF	CITATIONS
37	A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer. <i>Frontiers in Endocrinology</i> , 2020, 11, 490.	1.5	14
38	Multicenter Multireader Evaluation of an Artificial Intelligence-Based Attention Mapping System for the Detection of Prostate Cancer With Multiparametric MRI. <i>American Journal of Roentgenology</i> , 2020, 215, 903-912.	1.0	29
39	Combined MRI-targeted Plus Systematic Confirmatory Biopsy Improves Risk Stratification for Patients Enrolling on Active Surveillance for Prostate Cancer. <i>Urology</i> , 2020, 144, 164-170.	0.5	4
40	Prospective Evaluation of PI-RADS Version 2.1 for Prostate Cancer Detection. <i>American Journal of Roentgenology</i> , 2020, 215, 1098-1103.	1.0	17
41	Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 3672-3684.	0.8	78
42	Metastatic and recurrent adrenocortical cancer is not defined by its genomic landscape. <i>BMC Medical Genomics</i> , 2020, 13, 165.	0.7	15
43	Deep Learning-Based Artificial Intelligence for PI-RADS Classification to Assist Multiparametric Prostate MRI Interpretation: A Development Study. <i>Journal of Magnetic Resonance Imaging</i> , 2020, 52, 1499-1507.	1.9	52
44	Twenty-five-Year Follow-up of a Prospective Randomized Trial Comparing Preoperative Versus Postoperative FLAC/Granulocyte Colony-Stimulating Factor Chemotherapy for Stage II Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 334-339.	0.6	0
45	Deep Learning Framework for Epithelium Density Estimation in Prostate Multi-Parametric Magnetic Resonance Imaging. , 2020, , .		2
46	Spatial density and diversity of architectural histology in prostate cancer: influence on diffusion weighted magnetic resonance imaging. <i>Quantitative Imaging in Medicine and Surgery</i> , 2020, 10, 326-339.	1.1	7
47	Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome: Spectrum of imaging findings. <i>Clinical Imaging</i> , 2020, 68, 14-19.	0.8	10
48	Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1099-1109.	5.1	59
49	A case report of multiple primary prostate tumors with differential drug sensitivity. <i>Nature Communications</i> , 2020, 11, 837.	5.8	28
50	MRI-guided pelvic lymph node biopsy via transrectal approach in prostate cancer. <i>Urology Case Reports</i> , 2020, 30, 101129.	0.1	0
51	Growth Rates of Genetically Defined Renal Tumors: Implications for Active Surveillance and Intervention. <i>Journal of Clinical Oncology</i> , 2020, 38, 1146-1153.	0.8	39
52	Impact of bowel preparation with Fleet™ enema on prostate MRI quality. <i>Abdominal Radiology</i> , 2020, 45, 4252-4259.	1.0	26
53	Determination of the Expression of PD-L1 in the Morphologic Spectrum of Renal Cell Carcinoma. <i>Journal of Cancer</i> , 2020, 11, 3596-3603.	1.2	17
54	microRNA Expression Profiling in Young Prostate Cancer Patients. <i>Journal of Cancer</i> , 2020, 11, 4106-4114.	1.2	32

#	ARTICLE	IF	CITATIONS
55	Novel renal medullary carcinoma cell lines, <sc>UOK353</sc> and <sc>UOK360</sc>, provide preclinical tools to identify new therapeutic treatments. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 472-483.	1.5	7
56	Results from a phase II study of bevacizumab and erlotinib in subjects with advanced hereditary leiomyomatosis and renal cell cancer (HLRCC) or sporadic papillary renal cell cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5004-5004.	0.8	53
57	Adrenocortical carcinoma masquerading as pheochromocytoma: a histopathologic dilemma. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2020, 2020, .	0.2	5
58	PI-RADS® Category as a Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance. <i>Journal of Urology</i> , 2020, 204, 1229-1235.	0.2	5
59	Use of multiparametric <sc>magnetic resonance imaging</sc> and fusionâ€guided biopsies to properly select and follow Africanâ€American men on active surveillance. <i>BJU International</i> , 2019, 124, 768-774.	1.3	8
60	mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 352.e25-352.e30.	0.8	4
61	Interreader Variability of Prostate Imaging Reporting and Data System Version 2 in Detecting and Assessing Prostate Cancer Lesions at Prostate MRI. <i>American Journal of Roentgenology</i> , 2019, 212, 1197-1205.	1.0	75
62	Updated Recommendations on the Diagnosis, Management, and Clinical Trial Eligibility Criteria for Patients With Renal Medullary Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 1-6.	0.9	60
63	Do patients with familial nonmedullary thyroid cancer present with more aggressive disease? Implications for initial surgical treatment. <i>Surgery</i> , 2019, 165, 50-57.	1.0	21
64	CDC73 Germline Mutation in a Family With Mixed Epithelial and Stromal Tumors. <i>Urology</i> , 2019, 124, 91-97.	0.5	20
65	A Multireader Exploratory Evaluation of Individual Pulse Sequence Cancer Detection on Prostate Multiparametric Magnetic Resonance Imaging (MRI). <i>Academic Radiology</i> , 2019, 26, 5-14.	1.3	12
66	Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultrasound Fusion Biopsy. <i>Journal of Urology</i> , 2019, 201, 84-90.	0.2	24
67	A multiparametric magnetic resonance imaging-based virtual reality surgical navigation tool for robotic-assisted radical prostatectomy. <i>Turkish Journal of Urology</i> , 2019, 45, 357-365.	1.3	18
68	SAT-LB060 Clinical Presentation and Management of Primary Ovarian Carcinoids in Multiple Endocrine Neoplasia Type 1. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	0
69	Clinical presentation and management of primary ovarian neuroendocrine tumor in multiple endocrine neoplasia type 1. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2019, 2019, .	0.2	6
70	A Magnetic Resonance Imagingâ€Based Prediction Model for Prostate Biopsy Risk Stratification. <i>JAMA Oncology</i> , 2018, 4, 678.	3.4	141
71	Prospective comparison of PIâ€RADS version 2 and qualitative inâ€house categorization system in detection of prostate cancer. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 48, 1326-1335.	1.9	18
72	The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. <i>Cell Reports</i> , 2018, 23, 313-326.e5.	2.9	523

#	ARTICLE	IF	CITATIONS
73	Computer-aided diagnosis prior to conventional interpretation of prostate mpMRI: an international multi-reader study. <i>European Radiology</i> , 2018, 28, 4407-4417.	2.3	68
74	All over the map: An interobserver agreement study of tumor location based on the PI-RADSv2 sector map. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 48, 482-490.	1.9	31
75	Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 207-215.	5.1	167
76	CD38 knockout suppresses tumorigenesis in mice and clonogenic growth of human lung cancer cells. <i>Carcinogenesis</i> , 2018, 39, 242-251.	1.3	56
77	Morphological changes induced by intraprostatic PSA-based vaccine in prostate cancer biopsies (phase I). <i>Journal of Cellular Biochemistry</i> , 2018, 123, 107-115.	1.1	3
78	What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate. <i>Radiology</i> , 2018, 286, 186-195.	3.6	188
79	The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. <i>Cancer</i> , 2018, 124, 65-73.	2.0	27
80	Clinical impact of PSMA-based <sup>18</sup> F-DCFPyC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 4-11.	3.3	57
81	Successful Treatment of Estrogen Excess in Primary Bilateral Macronodular Adrenocortical Hyperplasia with Leuprolide Acetate. <i>Hormone and Metabolic Research</i> , 2018, 50, 124-132.	0.7	7
82	Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib. <i>Clinical Cancer Research</i> , 2018, 24, 753-765.	3.2	26
83	A Phase II Trial of Cytorreduction and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Adrenocortical Carcinoma. <i>Journal of Surgical Research</i> , 2018, 232, 383-388.	0.8	10
84	Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. <i>Journal of Clinical Oncology</i> , 2018, 36, 141.		214
85	Multiparametric MRI for the detection of local recurrence of prostate cancer in the setting of biochemical recurrence after low dose rate brachytherapy. <i>Diagnostic and Interventional Radiology</i> , 2018, 24, 46-53.	0.7	21
86	Incidental bladder cancers found on multiparametric MRI of the prostate gland: a single center experience. <i>Diagnostic and Interventional Radiology</i> , 2018, 24, 316-320.	0.7	12
87	The Unknown microRNA Expression of Male Breast Cancer. Similarities and Differences with Female Ductal Carcinoma. Their Role as Tumor Biomarker. <i>Journal of Cancer</i> , 2018, 9, 450-459.	1.2	9
88	Validation of PI-RADS Version 2 in Transition Zone Lesions for the Detection of Prostate Cancer. <i>Radiology</i> , 2018, 288, 485-491.	3.6	53
89	Combination of anthracyclines and anti-CD47 therapy inhibit invasive breast cancer growth while preventing cardiac toxicity by regulation of autophagy. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 69-82.	1.1	55
90	Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms for Predicting Adverse Pathology in Prostate Cancer. <i>Journal of Urology</i> , 2018, 200, 1041-1047.	0.2	66

#	ARTICLE	IF	CITATIONS
91	A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 77-85.	0.9	40
92	Comprehensive genomic and phenotypic characterization of germline <i>FH</i> deletion in hereditary leiomyomatosis and renal cell carcinoma. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 484-492.	1.5	21
93	Prospective Evaluation of PI-RADS <sup>®</sup> Version 2 Using the International Society of Urological Pathology Prostate Cancer Grade Group System. <i>Journal of Urology</i> , 2017, 198, 583-590.	0.2	127
94	Determinants and prognostic implications of malignant ascites in metastatic papillary renal cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 114.e9-114.e14.	0.8	7
95	Validation of the Dominant Sequence Paradigm and Role of Dynamic Contrast-enhanced Imaging in PI-RADS Version 2. <i>Radiology</i> , 2017, 285, 859-869.	3.6	126
96	Genomic and metabolic characterization of a chromophobe renal cell carcinoma cell line model (UOK276). <i>Genes Chromosomes and Cancer</i> , 2017, 56, 719-729.	1.5	14
97	Multiple Recurrent Paraganglioma in a Pediatric Patient with Germline SDH-B Mutation. <i>Urology Case Reports</i> , 2017, 13, 107-109.	0.1	1
98	Results of Screening in Familial Non-Medullary Thyroid Cancer. <i>Thyroid</i> , 2017, 27, 1017-1024.	2.4	47
99	Missing the Mark: Prostate Cancer Upgrading by Systematic Biopsy over Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Biopsy. <i>Journal of Urology</i> , 2017, 197, 327-334.	0.2	84
100	Tumor contact with prostate capsule on magnetic resonance imaging: A potential biomarker for staging and prognosis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 30.e1-30.e8.	0.8	42
101	Magnetic Resonance Imaging-Transrectal Ultrasound Guided Fusion Biopsy to Detect Progression in Patients with Existing Lesions on Active Surveillance for Low and Intermediate Risk Prostate Cancer. <i>Journal of Urology</i> , 2017, 197, 640-646.	0.2	90
102	Accuracy and agreement of PIRADSv2 for prostate cancer mpMRI: A multireader study. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 579-585.	1.9	170
103	Optimal high b-value for diffusion weighted MRI in diagnosing high risk prostate cancers in the peripheral zone. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 125-131.	1.9	38
104	Should Hypoechoic Lesions on Transrectal Ultrasound Be Sampled During Magnetic Resonance Imaging-targeted Prostate Biopsy?. <i>Urology</i> , 2017, 105, 113-117.	0.5	12
105	Prostate Cancer: A Correlative Study of Multiparametric MR Imaging and Digital Histopathology. <i>Radiology</i> , 2017, 285, 147-156.	3.6	33
106	Can index lesion tumor volume on T2 weighted MRI predict biochemical recurrence following radical prostatectomy?. <i>Journal of Clinical Oncology</i> , 2017, 35, 32-32.	0.8	0
107	Index lesion tumor volume on MRI to predict adverse pathologic outcomes following radical prostatectomy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 43-43.	0.8	0
108	Changes in prostate cancer detection rate of fusion versus systematic biopsy over time: A single center experience.. <i>Journal of Clinical Oncology</i> , 2017, 2017, 15-15.	0.8	0



#	ARTICLE	IF	CITATIONS
109	A model for predicting focal ablation candidates in patients with prostate cancer based on MRI and biopsy criteria.. Journal of Clinical Oncology, 2017, 35, 31-31.	0.8	0
110	Changes in prostate cancer detection rate of fusion versus systematic biopsy over time: A single center experience.. Journal of Clinical Oncology, 2017, 35, 15-15.	0.8	0
111	Midline lesions of the prostate: role of MRI/TRUS fusion biopsy and implications in Gleason risk stratification. International Urology and Nephrology, 2016, 48, 1445-1452.	0.6	9
112	Exercise-induced haemoptysis as a rare presentation of a rare lung disease. Thorax, 2016, 71, 865-868.	2.7	0
113	H255Y and K508R missense mutations in tumour suppressorfolliculin (FLCN)promote kidney cell proliferation. Human Molecular Genetics, 2016, 26, ddw392.	1.4	17
114	The significance of anterior prostate lesions on multiparametric magnetic resonance imaging in African-American men. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 254.e15-254.e21.	0.8	25
115	Efficiency of Prostate Cancer Diagnosis by MR/Ultrasound Fusion-Guided Biopsy vs Standard Extended-Sextant Biopsy for MR-Visible Lesions. Journal of the National Cancer Institute, 2016, 108, djw039.	3.0	68
116	Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection. Journal of Urology, 2016, 196, 690-696.	0.2	116
117	Application of an unsupervised multi-characteristic framework for intermediate-high risk prostate cancer localization using diffusion-weighted MRI. Magnetic Resonance Imaging, 2016, 34, 1227-1234.	1.0	4
118	Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters. Clinical Cancer Research, 2016, 22, 4989-5000.	3.2	15
119	Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2170-2175.	3.3	102
120	Prostate Cancer Diagnosis on Repeat Magnetic Resonance Imaging-Transrectal Ultrasound Fusion Biopsy of Benign Lesions: Recommendations for Repeat Sampling. Journal of Urology, 2016, 196, 62-67.	0.2	20
121	Reproducibility of Multiparametric Magnetic Resonance Imaging and Fusion Guided Prostate Biopsy: Multi-Institutional External Validation by a Propensity Score Matched Cohort. Journal of Urology, 2016, 195, 1737-1743.	0.2	18
122	PET/CT imaging of renal cell carcinoma with 18F-VM4-037: a phase II pilot study. Abdominal Radiology, 2016, 41, 109-118.	1.0	35
123	Correlation of magnetic resonance imaging with digital histopathology in prostate. International Journal of Computer Assisted Radiology and Surgery, 2016, 11, 657-666.	1.7	22
124	Combined Biparametric Prostate Magnetic Resonance Imaging and Prostate-specific Antigen in the Detection of Prostate Cancer: A Validation Study in a Biopsy-naive Patient Population. Urology, 2016, 88, 125-134.	0.5	81
125	Preoperative Multiparametric Magnetic Resonance Imaging Predicts Biochemical Recurrence in Prostate Cancer after Radical Prostatectomy. PLoS ONE, 2016, 11, e0157313.	1.1	32
126	Isolated Large Cell Calcifying Sertoli Cell Tumor in a Young Boy, not Associated with Peutz-Jeghers Syndrome or Carney Complex. Annals of Clinical and Laboratory Research, 2015, 3, 2.	0.1	6



#	ARTICLE	IF	CITATIONS
127	Posterior subcapsular prostate cancer: identification with mpMRI and MRI/TRUS fusion-guided biopsy. <i>Abdominal Imaging</i> , 2015, 40, 2557-2565.	2.0	34
128	The Role of Image Guided Biopsy Targeting in Patients with Atypical Small Acinar Proliferation. <i>Journal of Urology</i> , 2015, 193, 473-478.	0.2	30
129	Primary Aldosteronism and <i>ARMC5</i> Variants. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E900-E909.	1.8	89
130	A Phase I Dosing Study of Ferumoxytol for MR Lymphography at 3 T in Patients With Prostate Cancer. <i>American Journal of Roentgenology</i> , 2015, 205, 64-69.	1.0	57
131	Upgrading prostate cancer following proton beam therapy. <i>Urology Annals</i> , 2015, 7, 262.	0.3	1
132	Prostate Cancer: Interobserver Agreement and Accuracy with the Revised Prostate Imaging Reporting and Data System at Multiparametric MR Imaging. <i>Radiology</i> , 2015, 277, 741-750.	3.6	296
133	Comparison of MR/Ultrasound Fusion-Guided Biopsy With Ultrasound-Guided Biopsy for the Diagnosis of Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 390.	3.8	1,267
134	Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 167.e13-167.e20.	0.8	24
135	The Role of Magnetic Resonance Image Guided Prostate Biopsy in Stratifying Men for Risk of Extracapsular Extension at Radical Prostatectomy. <i>Journal of Urology</i> , 2015, 194, 105-111.	0.2	56
136	Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 202.e1-202.e7.	0.8	133
137	Folliculin-interacting proteins Fnip1 and Fnip2 play critical roles in kidney tumor suppression in cooperation with Flcn. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E1624-31.	3.3	74
138	Mitochondrial DNA mutations distinguish bilateral multifocal renal oncocytomas from familial Birt-Hogg-Dub tumors. <i>Modern Pathology</i> , 2015, 28, 1458-1469.	2.9	23
139	18F-FLT PET/CT in the Evaluation of Pheochromocytomas and Paragangliomas: A Pilot Study. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1849-1854.	2.8	4
140	Magnetic Resonance Imaging/Transrectal Ultrasonography Fusion Prostate Biopsy Significantly Outperforms Systematic 12-Core Biopsy for Prediction of Total Magnetic Resonance Imaging Tumor Volume in Active Surveillance Patients. <i>Journal of Endourology</i> , 2015, 29, 1115-1121.	1.1	41
141	Does focal incidental 18F-FDG PET/CT uptake in the prostate have significance?. <i>Abdominal Imaging</i> , 2015, 40, 3222-3229.	2.0	22
142	Multiparametric magnetic resonance imaging-transrectal ultrasound fusion-assisted biopsy for the diagnosis of local recurrence after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 425.e1-425.e6.	0.8	32
143	Can mpMRI predict biochemical recurrence after radical prostatectomy? Implications for preoperative staging and surgical planning.. <i>Journal of Clinical Oncology</i> , 2015, 33, 161-161.	0.8	0
144	Performance of MRI-TRUS-guided fusion biopsy to detect progression on active surveillance for low- and intermediate-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 43-43.	0.8	0

#	ARTICLE	IF	CITATIONS
145	How reliable is a negative MRI/TRUS fusion biopsy? The predictive value of targeted biopsy for prostate cancer.. Journal of Clinical Oncology, 2015, 33, 51-51.	0.8	0
146	Magnetic resonance imaging-guided focal laser ablation for prostate cancer: A phase I trial.. Journal of Clinical Oncology, 2015, 33, e16128-e16128.	0.8	0
147	Targeting ABL1-Mediated Oxidative Stress Adaptation in Fumarate Hydratase-Deficient Cancer. Cancer Cell, 2014, 26, 840-850.	7.7	87
148	miR-145 suppresses thyroid cancer growth and metastasis and targets AKT3. Endocrine-Related Cancer, 2014, 21, 517-531.	1.6	91
149	Pathologic validation of renal cell carcinoma histology in the Surveillance, Epidemiology, and End Results program. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 23.e9-23.e13.	0.8	30
150	Lymphangitic Retroperitoneal Carcinomatosis Occurring From Metastatic Sarcomatoid Chromophobe Renal Cell Carcinoma. Urology Case Reports, 2014, 2, 39-42.	0.1	1
151	Identification of Threshold Prostate Specific Antigen Levels to Optimize the Detection of Clinically Significant Prostate Cancer by Magnetic Resonance Imaging/Ultrasound Fusion Guided Biopsy. Journal of Urology, 2014, 192, 1642-1649.	0.2	55
152	Molecular genetics and cellular features of TFE3 and TFEB fusion kidney cancers. Nature Reviews Urology, 2014, 11, 465-475.	1.9	227
153	Prediction of prostate cancer Gleason score using a MRI-based nomogram.. Journal of Clinical Oncology, 2014, 32, 255-255.	0.8	1
154	Diagnostic value of biparametric MRI as an adjunct to PSA-based detection of prostate cancer.. Journal of Clinical Oncology, 2014, 32, 193-193.	0.8	0
155	Utility of Multiparametric Magnetic Resonance Imaging Suspicion Levels for Detecting Prostate Cancer. Journal of Urology, 2013, 190, 1721-1727.	0.2	171
156	A Novel Germline Mutation in <i>BAP1</i> Predisposes to Familial Clear-Cell Renal Cell Carcinoma. Molecular Cancer Research, 2013, 11, 1061-1071.	1.5	135
157	Magnetic Resonance Imaging/Ultrasound Fusion Biopsy Significantly Upgrades Prostate Cancer Versus Systematic 12-core Transrectal Ultrasound Biopsy. European Urology, 2013, 64, 713-719.	0.9	436
158	Can Magnetic Resonance-Ultrasound Fusion Biopsy Improve Cancer Detection in Enlarged Prostates?. Journal of Urology, 2013, 190, 2020-2025.	0.2	73
159	Correlation of Magnetic Resonance Imaging Tumor Volume with Histopathology. Journal of Urology, 2012, 188, 1157-1163.	0.2	188
160	Multiparametric 3T Prostate Magnetic Resonance Imaging to Detect Cancer: Histopathological Correlation Using Prostatectomy Specimens Processed in Customized Magnetic Resonance Imaging Based Molds. Journal of Urology, 2011, 186, 1818-1824.	0.2	440
161	The Morphologic Spectrum of Kidney Tumors in Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC) Syndrome. American Journal of Surgical Pathology, 2007, 31, 1578-1585.	2.1	361
162	Protein expression profiling in the spectrum of renal tumors. FASEB Journal, 2007, 21, A181.	0.2	0

#	ARTICLE	IF	CITATIONS
163	A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma. <i>Cancer</i> , 2002, 94, 2333-2343.	2.0	1
164	3p21, 5q21, and 9p21 allelic deletions are frequently found in normal bronchial cells adjacent to non-small-cell lung cancer, while they are unusual in patients with no evidence of malignancy. <i>Journal of Pathology</i> , 2001, 195, 429-434.	2.1	22
165	A Phase I study of infusional vinblastine in combination with the p-glycoprotein antagonist PSC 833 (valsopodar). <i>Cancer</i> , 2001, 92, 1577-1590.	2.0	76
166	Detection of loss of heterozygosity at chromosome 3p25-26 in primary and metastatic ovarian clear-cell carcinoma: Utilization of microdissection and polymerase chain reaction in archival tissues. <i>Diagnostic Cytopathology</i> , 2001, 24, 328-332.	0.5	18
167	A Phase I study of infusional vinblastine in combination with the p-glycoprotein antagonist PSC 833 (valsopodar). , 2001, 92, 1577.		1
168	Squamous Cell Carcinoma of the Thyroid: An Aggressive Tumor Associated with Tall Cell Variant of Papillary Thyroid Carcinoma. <i>Modern Pathology</i> , 2000, 13, 742-746.	2.9	86
169	Loss of heterozygosity analysis to diagnose adrenal cortical carcinoma. , 1999, 87, 176-177.		0
170	Utilization of microdissection and the polymerase chain reaction for the diagnosis of adrenal cortical carcinoma in fine-needle aspiration cytology. , 1999, 87, 231-237.		12
171	The tall cell variant of papillary carcinoma of the thyroid. <i>Cancer</i> , 1999, 87, 238-242.	2.0	22
172	Clonality analysis of benign parathyroid lesions by human androgen receptor (HUMARA) gene assay. <i>Endocrine Pathology</i> , 1998, 9, 293-300.	5.2	18
173	Allelic Loss on Chromosome 8p in BRCA-1 Mutation Positive Breast/Ovarian Cancers. <i>Breast Journal</i> , 1998, 4, 9-12.	0.4	4
174	Genetic Changes Associated With Primary Merkel Cell Carcinoma. <i>American Journal of Clinical Pathology</i> , 1998, 109, 565-570.	0.4	47
175	PULMONARY INFARCTS CAN MIMIC PULMONARY METASTASES FROM RENAL CANCER. <i>Journal of Urology</i> , 1997, 158, 1688-1690.	0.2	11
176	GALECTIN-3 AND LAMININ EXPRESSION IN NEOPLASTIC AND NON-NEOPLASTIC THYROID TISSUE. , 1997, 181, 80-86.		128
177	Immunohistochemical expression of $\gamma$ -class glutathioneS-transferase is down-regulated in adenocarcinoma of the prostate. , 1997, 79, 1595-1599.		50
178	GALECTIN-3 AND LAMININ EXPRESSION IN NEOPLASTIC AND NON-NEOPLASTIC THYROID TISSUE. , 1997, 181, 80.		3
179	Role of endogenous interferon gamma in murine tumor growth and tumor necrosis factor alpha antitumor efficacy. <i>Annals of Surgical Oncology</i> , 1996, 3, 198-203.	0.7	9
180	Differential immunohistochemical detection of transforming growth factor $\beta$ , amphiregulin and CRIPTO in human normal and malignant breast tissues. , 1996, 65, 51-56.		95

#	ARTICLE	IF	CITATIONS
181	Differential immunohistochemical detection of transforming growth factor $\hat{\pm}$ , amphiregulin and CRIPTO in human normal and malignant breast tissues. <i>International Journal of Cancer</i> , 1996, 65, 51-56.	2.3	1
182	Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from non-malignant lesions. <i>Nature Medicine</i> , 1995, 1, 1257-1260.	15.2	298
183	Hereditary Papillary Renal Cell Carcinoma. <i>Journal of Urology</i> , 1994, 151, 561-566.	0.2	289
184	Age contrast in ovarian pathology. <i>Cancer</i> , 1993, 71, 537-544.	2.0	35
185	Small cell carcinoma of the endometrium with associated ocular paraneoplastic syndrome. <i>Cancer</i> , 1992, 69, 2283-2288.	2.0	66
186	Langerhans cell histiocytosis of the female genital tract. <i>Cancer</i> , 1991, 67, 1650-1660.	2.0	89
187	Endometrial carcinoma with trophoblastic differentiation. An aggressive form of uterine cancer. <i>Cancer</i> , 1991, 68, 1799-1802.	2.0	54
188	Positive gallium-67 citrate scintigraphy in Wiskott-Aldrich syndrome with malignant lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1991, 18, 928-930.	2.2	1
189	Preparative Cytoreductive Surgery in Patients with Metastatic Renal Cell Carcinoma Treated with Adoptive Immunotherapy with Interleukin-2 or Interleukin-2 Plus Lymphokine Activated Killer Cells. <i>Journal of Urology</i> , 1990, 144, 614-617.	0.2	90